Drug Approval | May 24, 2022
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
The revamped Ayushman Bharat Health Account (ABHA) mobile application offers added functionalities and a new User Interface (UI)
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Subscribe To Our Newsletter & Stay Updated
